What is Immuneering Corp's earnings per share (EPS)?

Immuneering Corp (IMRX) reported diluted earnings per share of $-1.27 for fiscal year 2025. This represents a 37.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Immuneering Corp Financials

IMRX

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows Immuneering Corp (IMRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMRX FY2025 2026-05-15

Immuneering is a cash-funded development business, with equity raises periodically resetting runway instead of revenue supporting operations.

In FY2025, operating cash burn of $45.3M was close to the net loss of $56.0M, so reported losses were consuming real cash rather than being cushioned by large non-cash charges. That reset came from external financing of $226.6M, which lifted cash to $128.6M and shows the balance sheet is being replenished outside the business rather than by operations.

The expense mix shows research is the main operating use of cash: FY2025 R&D was $42.0M versus SG&A of $17.3M. That cost shape looks like a program-building organization, where scientific work absorbs far more resources than commercial infrastructure.

The balance sheet is light on liabilities, with $13.5M of obligations against $218.5M of equity, so solvency pressure is low even while the company remains loss-making. The tighter issue is runway discipline: free cash outflow stayed heavy at $55.1M in FY2024 and $45.5M in FY2025, making liquidity more dependent on periodic capital access than on any self-funding cycle.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Immuneering Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Immuneering Corp carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 17.50, Immuneering Corp holds $17.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Immuneering Corp generates a -25.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -147.5% the prior year.

Piotroski F-Score Weak

3/9

Immuneering Corp passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, Immuneering Corp generates $0.81 in operating cash flow (-$45.3M OCF vs -$56.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$59.1M

YoY+7.3%

Immuneering Corp's EBITDA was -$59.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.3% from the prior year.

Net Income

-$56.0M

YoY+8.2%

Immuneering Corp reported -$56.0M in net income in fiscal year 2025. This represents an increase of 8.2% from the prior year.

EPS (Diluted)

$-1.27

YoY+37.7%

Immuneering Corp earned $-1.27 per diluted share (EPS) in fiscal year 2025. This represents an increase of 37.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$45.5M

YoY+17.4%

Immuneering Corp generated -$45.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 17.4% from the prior year.

Cash & Debt

$128.6M

YoY+255.9%

5Y CAGR+28.2%

Immuneering Corp held $128.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-25.6%

YoY+121.8pp

Immuneering Corp's ROE was -25.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 121.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$42.0M

YoY-12.3%

5Y CAGR+22.9%

Immuneering Corp invested $42.0M in research and development in fiscal year 2025. This represents a decrease of 12.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$142K

YoY+67.6%

5Y CAGR+21.6%

Immuneering Corp invested $142K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 67.6% from the prior year.

IMRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$0-100.0%	$317K-84.8%	$2.1M-10.0%	$2.3M
Cost of Revenue	N/A	N/A	$0-100.0%	$158K-86.3%	$1.2M-9.9%	$1.3M
Gross Profit	N/A	N/A	$0-100.0%	$159K-82.9%	$927K-10.1%	$1.0M
R&D Expenses	$42.0M-12.3%	$48.0M+15.2%	$41.6M+14.8%	$36.3M+36.6%	$26.5M+76.9%	$15.0M
SG&A Expenses	$17.3M+7.6%	$16.1M-4.1%	$16.8M+7.4%	$15.6M+88.7%	$8.3M+166.0%	$3.1M
Operating Income	-$59.4M+7.3%	-$64.1M-9.7%	-$58.4M-12.9%	-$51.7M-52.7%	-$33.9M-98.4%	-$17.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	N/A	-$307K	N/A
Net Income	-$56.0M+8.2%	-$61.0M-14.1%	-$53.5M-5.9%	-$50.5M-50.6%	-$33.5M-96.8%	-$17.0M
EPS (Diluted)	$-1.27+37.7%	$-2.04-8.5%	$-1.88+1.6%	$-1.91+22.4%	$-2.46+28.5%	$-3.44

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$10.6M	N/A	$10.9M+4.0%	$10.5M-8.9%	$11.5M	N/A	$11.3M+5.6%	$10.7M
SG&A Expenses	$4.7M	N/A	$4.5M+4.9%	$4.3M+7.3%	$4.0M	N/A	$4.0M-5.7%	$4.3M
Operating Income	-$15.3M	N/A	-$15.4M-4.2%	-$14.8M+4.7%	-$15.5M	N/A	-$15.3M-2.4%	-$14.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$13.5M	N/A	-$15.0M-3.7%	-$14.4M+4.1%	-$15.0M	N/A	-$14.6M-3.7%	-$14.1M
EPS (Diluted)	$-0.21	N/A	$-0.38+5.0%	$-0.40+4.8%	$-0.42	N/A	$-0.49-4.3%	$-0.47

IMRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$232.0M+340.1%	$52.7M-48.6%	$102.6M-16.2%	$122.4M-26.6%	$166.7M+333.9%	$38.4M
Current Assets	$176.2M+345.2%	$39.6M-55.6%	$89.1M-18.1%	$108.7M-28.6%	$152.3M+303.7%	$37.7M
Cash & Equivalents	$128.6M+255.9%	$36.1M-39.2%	$59.4M-18.2%	$72.6M-3.0%	$74.9M+101.9%	$37.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$0-100.0%	$12K-95.0%	$246K-50.8%	$500K
Goodwill	$6.7M0.0%	$6.7M0.0%	$6.7M0.0%	$6.7M-0.2%	$6.7M	N/A
Total Liabilities	$13.5M+19.2%	$11.3M-5.7%	$12.0M-4.1%	$12.5M+16.7%	$10.7M-82.4%	$60.9M
Current Liabilities	$10.1M+34.2%	$7.5M-4.4%	$7.8M-2.6%	$8.1M+43.0%	$5.6M+149.7%	$2.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$218.5M+427.9%	$41.4M-54.3%	$90.6M-17.5%	$109.9M-29.6%	$156.0M+793.8%	-$22.5M
Retained Earnings	-$280.3M-25.0%	-$224.3M-37.4%	-$163.3M-48.7%	-$109.8M-85.2%	-$59.3M-130.3%	-$25.7M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$214.8M-7.4%	$232.0M-3.8%	$241.1M+501.8%	$40.1M-21.0%	$50.7M-3.9%	$52.7M-23.1%	$68.6M-11.1%	$77.1M
Current Assets	$161.4M-8.4%	$176.2M-23.1%	$229.1M+726.3%	$27.7M-27.4%	$38.2M-3.5%	$39.6M-28.4%	$55.3M-13.2%	$63.7M
Cash & Equivalents	$47.3M-63.2%	$128.6M-43.5%	$227.6M+763.4%	$26.4M-26.5%	$35.9M-0.8%	$36.1M-20.0%	$45.2M-24.3%	$59.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.7M0.0%	$6.7M0.0%	$6.7M0.0%	$6.7M0.0%	$6.7M0.0%	$6.7M0.0%	$6.7M0.0%	$6.7M
Total Liabilities	$8.3M-38.6%	$13.5M+3.2%	$13.1M+17.6%	$11.1M+25.8%	$8.8M-22.0%	$11.3M+4.5%	$10.8M+0.5%	$10.8M
Current Liabilities	$5.0M-50.6%	$10.1M+5.5%	$9.5M+27.5%	$7.5M+46.6%	$5.1M-31.9%	$7.5M+8.4%	$6.9M+2.0%	$6.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$206.5M-5.5%	$218.5M-4.2%	$228.0M+687.9%	$28.9M-30.8%	$41.8M+1.1%	$41.4M-28.3%	$57.7M-12.9%	$66.3M
Retained Earnings	-$293.8M-4.8%	-$280.3M-4.3%	-$268.7M-5.9%	-$253.8M-6.0%	-$239.3M-6.7%	-$224.3M-8.8%	-$206.2M-7.6%	-$191.6M

IMRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$45.3M+17.6%	-$55.0M-12.3%	-$49.0M-11.0%	-$44.1M-42.9%	-$30.9M-111.0%	-$14.6M
Capital Expenditures	$142K+67.6%	$85K-75.2%	$343K-53.8%	$742K+1121.5%	$61K+13.8%	$53K
Free Cash Flow	-$45.5M+17.4%	-$55.1M-11.7%	-$49.3M-10.0%	-$44.8M-45.1%	-$30.9M-110.7%	-$14.7M
Investing Cash Flow	-$88.7M-435.7%	$26.4M+262.3%	$7.3M-82.6%	$41.8M+155.3%	-$75.6M-141463.2%	-$53K
Financing Cash Flow	$226.6M+4172.3%	$5.3M-81.4%	$28.4M+149558.4%	$19K-100.0%	$144.3M+279.8%	$38.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$18.4M-87.3%	-$9.8M+17.8%	-$12.0M-26.8%	-$9.4M+32.9%	-$14.1M+3.0%	-$14.5M-7.7%	-$13.5M-16.9%	-$11.5M
Capital Expenditures	$80K-35.5%	$124K+1607.9%	$7K+242.9%	$2K-76.3%	$9K-4.4%	$9K+77.6%	$5K-83.9%	$33K
Free Cash Flow	-$18.5M-85.8%	-$10.0M+16.9%	-$12.0M-26.8%	-$9.4M+32.9%	-$14.1M+3.0%	-$14.5M-7.7%	-$13.5M-16.6%	-$11.6M
Investing Cash Flow	-$63.1M+28.9%	-$88.7M-1222779.8%	-$7K-242.9%	-$2K+76.3%	-$9K-100.2%	$5.5M+201.4%	-$5.4M-209.0%	$5.0M
Financing Cash Flow	$181K+150.6%	-$358K-100.2%	$213.2M+344191.3%	-$62K-100.4%	$13.8M+33794.2%	-$41K-100.9%	$4.4M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	50.1%+5.5pp	44.6%-0.1pp	44.6%
Operating Margin	N/A	N/A	N/A	-16325.8%-14696.6pp	-1629.2%-890.2pp	-739.0%
Net Margin	N/A	N/A	N/A	-15937.3%-14325.0pp	-1612.3%-875.2pp	-737.2%
Return on Equity	-25.6%+121.8pp	-147.5%-88.5pp	-59.0%-13.1pp	-46.0%-24.5pp	-21.5%	N/A
Return on Assets	-24.1%+91.6pp	-115.8%-63.7pp	-52.1%-10.8pp	-41.3%-21.2pp	-20.1%+24.2pp	-44.4%
Current Ratio	17.50+12.2	5.28-6.1	11.35-2.1	13.50-13.5	27.04+10.3	16.73
Debt-to-Equity	0.06-0.2	0.27+0.1	0.13+0.0	0.11+0.0	0.07+2.8	-2.71
FCF Margin	N/A	N/A	N/A	-14148.4%-12662.3pp	-1486.2%-851.3pp	-634.8%

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-6.5%	N/A	-6.6%+43.3pp	-49.9%-13.9pp	-36.0%	N/A	-25.3%-4.1pp	-21.2%
Return on Assets	-6.3%	N/A	-6.2%+29.8pp	-36.0%-6.3pp	-29.7%	N/A	-21.3%-3.0pp	-18.3%
Current Ratio	32.45+15.0	17.50-6.5	24.00+20.3	3.70-3.8	7.48+2.2	5.28-2.7	7.99-1.4	9.39
Debt-to-Equity	0.04-0.0	0.060.0	0.06-0.3	0.38+0.2	0.21-0.1	0.27+0.1	0.19+0.0	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Rocket Pharmaceu RCKT

$371.3M

Tectonic Therapeutic Inc TECX

$562.3M

Fulcrum Therapeutics FULC

$473.8M

Larimar Therapeutics Inc LRMR

$404.1M

Assembly Bioscie ASMB

$481.5M

Frequently Asked Questions

Is Immuneering Corp profitable?

No, Immuneering Corp (IMRX) reported a net income of -$56.0M in fiscal year 2025.

What is Immuneering Corp's EBITDA?

Immuneering Corp (IMRX) had EBITDA of -$59.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Immuneering Corp's return on equity (ROE)?

Immuneering Corp (IMRX) has a return on equity of -25.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Immuneering Corp's free cash flow?

Immuneering Corp (IMRX) generated -$45.5M in free cash flow during fiscal year 2025. This represents a 17.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Immuneering Corp's operating cash flow?

Immuneering Corp (IMRX) generated -$45.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Immuneering Corp's total assets?

Immuneering Corp (IMRX) had $232.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Immuneering Corp's capital expenditures?

Immuneering Corp (IMRX) invested $142K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Immuneering Corp spend on research and development?

Immuneering Corp (IMRX) invested $42.0M in research and development during fiscal year 2025.

What is Immuneering Corp's current ratio?

Immuneering Corp (IMRX) had a current ratio of 17.50 as of fiscal year 2025, which is generally considered healthy.

What is Immuneering Corp's debt-to-equity ratio?

Immuneering Corp (IMRX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Immuneering Corp's return on assets (ROA)?

Immuneering Corp (IMRX) had a return on assets of -24.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Immuneering Corp's cash runway?

Based on fiscal year 2025 data, Immuneering Corp (IMRX) had $128.6M in cash against an annual operating cash burn of $45.3M. This gives an estimated cash runway of approximately 34 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Immuneering Corp's Piotroski F-Score?

Immuneering Corp (IMRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Immuneering Corp's earnings high quality?

Immuneering Corp (IMRX) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Immuneering Corp?

Immuneering Corp (IMRX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.